Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations

Ruyi Shao\textsuperscript{a,*}, Yeiben Wang\textsuperscript{b,*}, Laifeng Li\textsuperscript{b}, Yongqiang Dong\textsuperscript{c}, Jiayi Zhao\textsuperscript{d} and Wenqing Liang\textsuperscript{d} \textsuperscript{\&}

\textsuperscript{a}Department of Orthopedics, Zhuji People’s Hospital, Shaoxing, Zhejiang, China; \textsuperscript{b}Department of Traumatic Orthopedics, Affiliated Jinan Third Hospital of Jining Medical University, Jinan, Shandong, China; \textsuperscript{c}Department of Orthopaedics, Xinchang People’s Hospital, Shaoxing, Zhejiang, China; \textsuperscript{d}Department of Orthopedics, Zhoushan Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, 355 Xinqiao Road, Dinghai District, Zhoushan 316000, Zhejiang, China

ABSTRACT
Primary bone tumors especially, sarcomas affect adolescents the most because it originates from osteoblasts cells responsible for bone growth. Chemotherapy, surgery, and radiation therapy are the most often used clinical treatments. Regrettably, surgical resection frequently fails to entirely eradicate the tumor, which is the primary cause of metastasis and postoperative recurrence, leading to a high death rate. Additionally, bone tumors frequently penetrate significant regions of bone, rendering them incapable of self-repair, and impairing patients’ quality of life. As a result, treating bone tumors and regenerating bone in the clinic is difficult. In recent decades, numerous sorts of alternative therapy approaches have been investigated due to a lack of approved treatments. Among the novel therapeutic approaches, hydrogel-based anticancer therapy has cleared the way for the development of new targeted techniques for treating bone cancer and bone regeneration. They include strategies such as co-delivery of several drug payloads, enhancing their biodistribution and transport capabilities, normalizing accumulation, and optimizing drug release profiles to decrease the limitations of current therapy. This review discusses current advances in functionalized hydrogels to develop a new technique for treating bone tumors by reducing postoperative tumor recurrence and promoting tissue repair.

1. Introduction
Bone cancer is a type of tumor that develops in the bone and kills normal bone tissues. It might be benign or cancerous. The tumor grows and compresses the normal bone tissues in both cases, however benign tumors lack the ability to metastasize and therefore do not spread to other organs of the body. Benign bone tumors can progress to malignancy and pose a risk if remain untreated. Benign bone tumors include osteochondroma, osteoma, osteoblastoma, fibrous dysplasia, and enchondroma (Hakim et al., 2015). According to the World Health Organization (WHO), bone cancers are classified as primary or secondary tumors (Sisu et al., 2012) and categorized over 45 distinct forms of bone tumors in 2002 based on their findings. Among the many kinds of bone tumors, Osteosarcoma is the most common and major type of bone tumor, accounting for 31.5% of all cases, followed by angiosarcoma (1.4%), malignant fibrous histiocytoma (5.7%), chondroma (8.4%), Ewing’s sarcoma (16%), and chondrosarcoma (25.8%) (Sisu et al., 2012; Jemal et al., 2005). Secondary bone tumors are usually malignant and develop as a result of soft tissue metastasizing tumors in the breast, liver, or lung. As per the American Cancer Society, the number of joint and bone cancer diagnoses and deaths rises each year (Miller et al., 2019).

Chemotherapy is the traditional postoperative treatment for bone tumors. Moreover, these drugs have the potential to cause systemic adverse effects such as liver failure, bone marrow suppression, and cardiac toxicity. Bone tumor therapy merges the complicated problems of tumor therapy with bone regeneration, which requires treatment with functionalized biomaterials. By developing novel alternate tumor therapy strategies based on biomaterials, these undesirable effects can be avoided by targeted delivery (Darge et al., 2019; Fan et al., 2019; Liao et al., 2020). But it is difficult to develop innovative techniques capable of preventing tumor recurrence while also promoting bone formation, requiring a multidisciplinary background to the research (Liu et al., 2019; Xue et al., 2020). However, researchers throughout the world have focused their efforts on finding solutions to these therapy’s issues for bone tumors and developing new therapeutic techniques which possess a great promise for developing treatments for bone malignancies, even though they are still in the initial phases of development.
Hydrogels are water-swellable polymeric materials having a three-dimensional (3D) network structure synthesized by crosslinking hydrophilic polymers. Hydrogels have a porous structure similar to that of the extracellular matrix (ECM), are biocompatible, and capable of loading growth factors, which results in effective bone defect repair. As such, they can be utilized as carrier materials for cells proliferation or bone growth to enhance the growth factors in bone tissue. Additionally, because its soft texture is similar to that of many soft biological tissues, it can help to lower the inflammatory reactions of nearby cells and tissues (Buwalda et al., 2017; Liu et al., 2019). Numerous researches have demonstrated the potential for hydrogels to be used in bone tissue regeneration. To be effective in treating bone cancers, the hydrogel should also have the potency to overcome tumor proliferation. It is strongly recommended that drugs or components be injected into the resected tumor region (Wu et al., 2018; Yang et al., 2020). Hydrogels may be used to deliver drugs in a sustained manner for tumor illumination (Ali Gumustas et al., 2016). Thus, hydrogels have established themselves as fascinating materials due to their remarkable biological activities and features. Numerous materials, including natural, synthetic, and hybrid polymers, have all been extensively used as the primary component of hydrogel for bone tumor therapy and tissue engineering (Culebras et al., 2021; Ma et al., 2021; Xu et al., 2021). Collagen, chitosan, hyaluronic acid (HA), gelatin, and sodium alginate are natural hydrogels that exhibit a high degree of biocompatibility, making them appealing biomedical materials for bone repair. Hydrogels derived from synthetic polymers including polyethylene, polylactic acid (PLA), polyethylene glycol (PEG), poly-vinyl alcohol (PVA), and poly-caprolactone have a variable microstructure, a long shelf life, and high mechanical strength but lack biological activity. As a result, hydrogels are excellent options for bone restoration and cancer therapy. Certain hydrogels combine internal antitumor action and localized delivery in a single mechanism (Zhao et al., 2020). Hydrogels can be used to treat localized cancers without the need for oral or intravenous chemotherapy (Chen et al., 2019; Fu et al., 2019). The advancement of multifunctional hydrogels has expanded their uses beyond tissue repair to include bone repair and tumor cure. The perfect hydrogel scaffold must meet certain criteria, including biocompatibility, injectability, adherence to the cavities, high mechanical qualities, and porous structure (Yu & Ding, 2008). Among these, an injectable hydrogel can be used to fill or match irregular flaws using a noninvasive moderate gelation technique (Cui et al., 2020; Wasupalli & Verma, 2020).

This review describes various classes of bone cancers, the design of hydrogels, the evolution of hydrogels technology, and current advances in the use of functionalized hydrogels for bone tumor therapy. The main material discusses novel ways for the formation and treatment of functionalized hydrogels. The treatment of bone tumors with functionalized hydrogels is a critical area of research for bone tissue engineering. Additionally, functionalized hydrogels will be critical in the treatment of complicated diseases that incorporate both tumor therapy and tissue engineering (such as adipose tissue, bone, and skin tissue engineering, etc.).

2. Bone cancer types

Bone cancers can broadly be divided into primary bone cancers (sarcomas) and secondary bone cancers (metastatic tumors of the bones). The predominant primary bone cancers which constitute nearly two-thirds of cancers include chondrosarcomas, osteosarcomas, and Ewing sarcomas. Primary bone cancers originate from primitive mesenchymal cells in the bones accounting for nearly 0.2% of all malignancies around the world. Secondary bone cancers occur due to various other advanced cancers in the body which spreads to the bones (Fan et al., 2019). The following section describes various types of these cancers to have a deeper understanding of the differences among them (Badilà et al., 2021).

2.1. Bone sarcomas

Sarcomas are primary bone tumors originating from rich cell populations due to close interaction between cancer cells and local microenvironments’ cell types, e.g. mesenchymal stem cells, osteoblasts, cancer-associated fibroblasts, osteocytes, chondrocytes, osteoclasts, or immune infiltrates (Menéndez et al., 2021; Tzanakakis et al., 2021). The most common primary bone cancers are Ewing sarcomas, chondrosarcomas, and osteosarcomas constituting 16, 25, and 35% respectively of malignant primary bone tumors (Cortini et al., 2019; Menéndez et al., 2021). These tumors are rarely occurring and comprise overall <0.2% of all diagnosed cancers with an approximate incidence rate of around 0.9 per 100,000 individuals annually for all joint and bone malignancies (Franchi, 2012; Menéndez et al., 2021). Although they less frequently occur, they are challenging have high mortality rates, and pose an overall burden on healthcare sectors (Cortini et al., 2019; Thanindratarn et al., 2019). Sarcomas consist of diverse cells populations, including cancer stem cells (CSCs). CSCs have certain features of normal stem cells e.g. differentiation capacity and self-renewal. These CSCs can more precisely be termed ‘tumor-initiating cells’ because they can generate nearly all cell types usually present in a tumor (Steinbichler et al., 2018). Thus, CSCs produce a broad range of markers depending on the tissue of origin and cancer type (Fujiwara & Ozaki, 2016; Steinbichler et al., 2018).

2.1.1. Osteosarcoma

The most frequently occurring primary bone tumor in young adults and adolescents is the osteosarcoma (Fujiwara & Ozaki, 2016; Tzanakakis et al., 2021). It has been reported that osteosarcoma predominantly occurs during the adolescent growth spurt, especially in the second decade of life with peak incidence cases at 16 and 18 years of life for girls and boys respectively (Taran et al., 2017). Osteosarcoma is regarded as aggressive cancer with a natural metastatic tendency where malignant cells lead to the formation of
pathological bones (Gambera et al., 2021). Disorganized bone structures formation is the characteristic of this cancer presented with irregular clumps of osteoid or fine lacey trabecular pattern markedly different from the normal bone formation. The most commonly affected bones are the long rapidly growing ones including that of the juxta-epiphyseal regions (Rajani & Gibbs, 2012). No significant improvements in the survival rate of patients with osteosarcoma has been seen over the last few decades regardless of the use of multimodal and aggressive treatments with around 68% median five-year survival rate (Bădiilă et al., 2021; Siegel et al., 2021). Chemo-resistance and prevention of metastasis are the most important challenges that impede the successful therapy of osteosarcoma (Miwa et al., 2021; Tzanakis et al., 2021).

2.1.2. Ewing sarcoma
Ewing sarcoma usually affects individuals in the initial 30 years of age and is characterized by round, small blue cells malignancy (Rajani & Gibbs, 2012). It is considered the second most frequently occurring malignant bone cancer in adolescents and children, with peak incidence at 15 years (Rajani & Gibbs, 2012; Thanindratarn et al., 2019; Tzanakis et al., 2021). Adjuvant chemotherapy, local treatments (surgical or radiotherapy interventions), and neo-adjuvant chemotherapy are the conventional treatment approaches for such tumors. Surgical resection in healthy margins is preferred over radiotherapy alone (Thévenin-Lemoine et al., 2018). For localized Ewing sarcoma, the overall five-year survival rate is 70 to 80%, however, worse patient outcomes are observed in cases where large tumors, pelvic involvement, or incomplete tumor regression after chemotherapy is observed (Thanindratarn et al., 2019).

2.1.3. Chondrosarcomas
Chondrosarcomas are mesenchymal cells tumors constituting nearly 10 to 20% of all malignant bone cancers. These tumors are characterized by distinctly differentiated cells with cartilage-like presentations (Rajani & Gibbs, 2012; Boehme et al., 2018). In contrast to Ewing sarcoma and osteosarcoma, this cancer is frequently diagnosed in adults over 40 years of age having more than 70% of confirmed cases in this age group (Zajac et al., 2021). Nevertheless, these are a group of heterogeneous tumors, both in terms of morphology and clinical presentations where nearly 10% constitute highly aggressive de-differentiated chondrosarcomas while the remaining 80–90% are conventional chondrosarcomas. Conventional chondrosarcomas frequently affect the femur, pelvis, ribs, humerus, and ilium. However, de-differentiated chondrosarcomas also affect the humerus, femur, and pelvis usually affecting non-chondroid and chondroid segments of these bones with osteoblastic or fibroblastic tissue presentation, indicative of two mesenchymal cell types differentiation in one tumor (Boehme et al., 2018; Zajac et al., 2021). In addition, chondrosarcomas have usually a high tendency for metastasis to distant organs and usually metastasize to lungs (Tzeng et al., 2021). These tumors are diagnosed later in the disease stage due to the formation of anatomically deep lesions and combined with high resistance to conventional treatments (radiotherapy and chemotherapy) and even to targeted therapies resulting in poor prognoses (Rajani & Gibbs, 2012; Boehme et al., 2018; Miwa et al., 2021). Thus, the treatment options for chondrosarcoma are very limited where surgical resection is considered the only choice for such tumors in most cases (Miwa et al., 2021; Zajac et al., 2021).

2.2. Bone metastases
The treatment of cancer becomes extremely difficult especially when metastasis occurs and it remains the most serious threat to human beings (Zhang et al., 2020). Bone is among the third most common sites in cancer patients and indicates a short prognosis with a mortality rate. It can occur in every type of cancer, however, is most commonly seen in prostate, breast, and lung cancer patients. Bone metastases are very painful and often cause significant morbidity represented by a wide range of skeletal events associated with considerable use of health resources (Svensson et al., 2017). The high morbidity and mortality of bone metastasis are because once tumor cells invade the bone and make a firm home in the skeleton, it can then rarely be treated successfully (Bădiilă et al., 2021). Nevertheless, treatment is yet considered for pain alleviation and slowing metastasis development in such patients (Macedo et al., 2017; Ferracini et al., 2018; Cortini et al., 2019). Metastases and sarcoma represent similar niches and tissue microenvironments (Cortini et al., 2019). Growing evidences suggest that tumor cells remain dormant for decades in metastatic niche prior to their proliferation and metastasis development. Bone metastases cancer cells cannot directly destroy bones; however, they cause osteoclasts stimulation which leads to degradation of the bone extracellular matrix.

3. Conventional bone tumor therapy
Surgery, chemotherapy, and radiotherapy are the major treatments options for common malignant bone tumors. The morbidities due to bone tumors have faced a slow-down due to current treatments including chemotherapy, radiation therapy, and surgical treatments. Yet, these conventional treatment modalities owe a plethora of shortcomings (e.g. severe side effects, tumor recurrence, multi-drug resistance, large bone defects induction), thus limiting their efficacy (Bădiilă et al., 2021). Tumor surgery’s purpose is to completely resect the disease via substantial tumor excision, and cure requires total surgical resection. Amputation and limb salvage are two subcategories of surgical treatments. Even after surgical amputation, less than 20% of patients with high-grade conventional osteosarcoma survived without chemotherapy, showing the presence of preoperative micrometastases (typically pulmonary). If the final pathology shows that the tumor is low grade, excision is usually all that is necessary to treat it, and chemotherapy is avoided in such a case. Radiation therapy is a contentious topic in osteosarcoma
Chemotherapy is one of the most important treatment options for osteosarcoma. Before the 1970s, osteosarcoma was not treated with chemotherapy, and mortality rates were extremely low. MD Anderson reported a 1972 study demonstrating a 50% mortality rate for osteosarcoma patients treated with chemotherapy over two years. In 1981, a prospective experiment was initiated to compare the outcomes of 32 patients treated with adriamycin (ADM), MTX (high dose), or bleomycin, actinomycin-D combinations, and Cytoxan to 27 patients treated without adjuvant chemotherapy (Misaghi et al., 2018). Various chemotherapy techniques have been investigated during the previous three decades and the procedure reported in the 1970s and early 1980s markedly increased survival rates of patients (Chou et al., 2008; Jaffe, 2009). A research group at Memorial Sloan Kettering Cancer Center established neo-adjuvant treatment and published numerous sequential series with progressively advanced chemotherapy regimens, such as that of the T-10 protocol (Meyers et al., 1992). The latter was carried out by multi-institutional organizations in the USA and Europe, which carried out confirmatory tests. Simultaneously, several investigations were carried out employing alternative multi-drug regimens (Ferguson & Goorin, 2001). All of these efforts ultimately resulted in the development of the multi-agent neo-adjuvant strategy in combination with adjuvant chemotherapy.

The radiotherapy for bone cancer could cause bone death or osteoradionecrosis. In addition, radiotherapy can also induce new cancer in the exposed area (Hosoya et al., 2008). Chemotherapy is usually the traditional treatment for postsurgical bone cancer treatment. However, chemotherapeutic drugs are associated with severe systemic adverse effects including cardiotoxicity, liver damage, and suppression of bone marrow. The development of novel nanomaterials-based alternative or supplementary tumor treatment strategies can bypass these adverse effects by targeted delivery (Liao et al., 2021). Additionally, the traditional anticancer drugs are washed out quickly from blood being attacked by the immune system and macrophages. Thus, these agents remain for a very short time in the circulation and could not sufficiently confront cancerous cells rendering the chemotherapy nearly ineffective. Moreover, the majority of the conventional anticancer drugs are poor aqueous soluble making them unable to traverse bio-membranes and are thus poor bioavailable (Mousa & Bharali, 2011). The overexpression of multi-drug resistance proteins on tumors (e.g., P-glycoprotein) is another problem encountered in the treatment of cancers because these proteins work as efflux pumps, preventing drug accumulation inside tumors and leading to decreased therapeutic output (Brown & Links, 1999; Krishna & Mayer, 2000; Davis et al., 2010). Nanotechnology-based treatments are now being adopted to help address these issues associated with anticancer drugs and make them able to pass through biological barriers and successfully mediate molecular interactions. Nanomaterials have excellent desirable features including large surface area and modifiable properties compared to conventional materials. Such materials include hydrogels, polymeric micelles, liposomes, dendrimers, nanotubes, and so on. Many of these nanotechnology-based products are already marketed and some are under research and evaluation for successful translation into clinics (Park, 2007; Praetorius & Mandal, 2007). For instance, calcium carbonate (CaCO₃)- crosslinked hyaluronic acid (HA) nanoparticle was prepared via a ‘green’ process with responsive behavior toward tumor microenvironment to effectively deliver doxorubicin for the treatment of various stages of osteosarcoma. The developed system exhibited the triggered release at target site with improved survival time, and reduced adverse effects (Zhang et al., 2018). Reduction -responsive polypeptide micelles based on methoxy poly(ethylene glycol) -block-poly(S-tert-butylmercapto-L-cysteine) copolymers (mPEG113-b-PBMLC 4, P4M, and mPEG113- b-PBMLC 9, P9M) were developed to control the delivery of doxorubicin in OS therapy (Yin et al., 2020). Curcumin (CUR) and cisplatin (CDDP) are co-incorporating in CaCO₃ nanoparticles using an easy one-pot strategy in sealed containers and in situ synthesized polydopamine (PDA) as a template for enhancing mitochondrial dysfunction caused by Ca²⁺ overload in cancer therapy while minimizing unwanted off-target consequences (Zheng et al., 2021).

4. Current hydrogel-based strategies for the bone tumors therapy

The high proliferative and penetrating ability of cancer cells (osteosarcoma) continues to be the main cause of the long-term survival rate of patients associated with osteosarcoma. As a result, new therapeutic options for osteosarcoma are critically needed. The development and applications of nanomaterials in bone ailments have already displayed promising potential. Biomaterials used in bone tumor therapy must accomplish the tasks such as they must target and killing tumor cells as well as stimulating bone repair. Among the various scaffolds used for bone tumors, hydrogels show more benefits over the other counterpart nanosystems and thus are considered the recent research hotspot. These materials show excellent biocompatibility, good drug-loading capacity, biodegradability, and programmable drug release potential and more importantly show less toxicity than other carrier systems (Chindamo et al., 2020). Advances in technology have made hydrogel’s production and application more efficient over the past few decades, and one of the most important branches has been used in biological tissue
regeneration. These advancements open up new avenues for overcoming the disadvantages of conventional bone repair materials, such as their poor mechanical characteristics and limited bioactivity, through rational design and manufacture of hydrogels with desirable topologies and characteristics. Recently, hybrid and multifunctional or bi-functional hydrogels have been developed to simultaneously enhance new tissue formation post-surgical resection of the tumor as well as prevent its recurrence (Liao et al., 2021; Chen et al., 2022). Multifunctional hydrogels for bone regeneration have also been reported recently which showed better and faster bone repair results in vivo in the rabbit model (Liu et al., 2020). Luo et al reported the synthesis of polydopamine and cisplatin decorating an n-HA surface loaded in chitosan/alginate hydrogels for photothermal therapy and chemotherapy for 4T1 breast tumor-bearing mice (Luo et al., 2019) (Figure 1). These reports indicate the excellent potential of hydrogels for effective bone tumor therapy and regeneration.

### 4.1. Design strategies of hydrogels for bone diseases and tissue engineering

The hydrogels’ development has seen four developmental stages as shown in Figure 2. For the first time in 1960, Wichterle and Lim reported the porous synthetic polymer of poly-2-hydroxyethylmethacrylate (PHEMA) to retain high water content and adjustable mechanical characteristics which they successfully used in contact lenses (Wichterle & Lim, 1960; Buwalda et al., 2014). Subsequently, research on hydrogels grown and shifted from simple single polymer networks e.g. poly(vinyl alcohol) (PVA), poly(ethylene glycol) (PEG), and PHEMA to stimulus-responsive and in situ second-generation hydrogels (Hodgson et al., 2017). The pluronic hydrogel was prepared by Nalbandian et al. (1972) which could be employed as artificial skin in treating thermal burns and used for the controlled release of silver lactate or silver nitrate antimicrobials. In the third-generation hydrogels, physical interactions e.g. inclusion complexation and stereocomplexation were utilized as crosslinking tools in combination with hydrophobic interactions to improve and fine-tune the release characteristics (targeted release) of hydrogels (Buwalda et al., 2017). An oligolactic acid side chain stereo-complex hydrogel was prepared by van Nostrum et al. (2004) with phosphonated hydrolytic polymaleic anhydride which showed a considerably longer degradation time compared with dextran stereo-ploycomplex hydrogels. At present, advanced chemical techniques of polymer and organic chemistry and nanotechnology are applied in hydrogels’ research which yields the development of fourth-generation hydrogels with exceptional structural and new functional features, suggesting their use for more accurate and targeted delivery to bone and other tissues (Buwalda et al., 2014).

### 4.2. Components and sources of hydrogel materials

Hydrogels can broadly be categorized into various types depending on their different properties including polymeric composition, sources, crosslinking types, degradation rates, physical properties, network charge, and responsiveness to environmental conditions as shown in Figure 3. Hydrogels can be prepared from natural materials obtained from natural sources and synthetic materials synthesized via the use of synthetic chemistry and chemical reactions (Ahmed, 2015). Most natural polymers are aqueous soluble and hydrogels...
made from natural source polymers generally show good biodegradability and biocompatibility (He et al., 2018). The lipophobic surfaces of natural polymers allow easy cells adherence, proliferation, and differentiation, however, the stability and mechanical properties of such materials are poor (Huang & Yang, 2008). Natural polymers commonly used for hydrogels synthesis include Gelatin (Chen et al., 2004), alginate (Kolambkar et al., 2011), hyaluronic acid (Li et al., 2015), chitosan, and dextran (Cascone et al., 1999), to mention a few. A gelatin hydrogel was prepared by Sasaki et al. (2013) containing basic fibroblast growth factor (bFGF) and demonstrated that the hydrogel was safe for the injured site and it can promote proximal sesamoid fractures healing. They also suggested that by controlling the degree of hydrogels crosslinking, its degradation can be controlled.

Synthetic polymer-based hydrogels can control synthesis and advantages of reproducibility (Amini & Nair, 2012). Nevertheless, the material safety and biocompatibility of synthetic polymers are the main issues. In addition, synthetic polymers possess inferior biological activities in comparison with natural biomaterials (Qing et al., 2013). Polyethylene glycol (PEG), poly-caprolactone (PCL), poly (N-isopropylacrylamide) (PNIPAAm), poly(L-glutamic acid) (PGA), polypropylene fiber (PPF), and poly-vinyl alcohol (PVA) are the examples of most common synthetic polymers used for the production of hydrogels (Yue et al., 2020). PEG is a promising polymer able to bind to lipophilic biodegradable polymers e.g. PCL and poly(lactic acid) (PLA) and create amphiphilic polymer biomaterials for bone and tissue engineering (Wang et al., 2019). The synthetic materials can be combined in different proportions for the construction of desired features hydrogels system. A triblock copolymer of PEG-PCL-PEG (PECE) combined with collagen and nano-hydroxyapatite (n-HA) based thermosensitive injectable hydrogel system was prepared by Fu et al. (2012) which combines the advantageous features of

---

**Figure 2.** Developmental stages and evolution of hydrogels.

**Figure 3.** Classification of hydrogels based on various features.

**Figure 4.** A schematic representing the progress of 3D bioprinting techniques (Vanaei et al., 2021).
PECE hydrogels, collagen, and n-HA fillers and demonstrated excellent bone regeneration property in comparison with natural repairing process.

Hydrogels can be divided into homo-polymeric, co-polymeric, interpenetrating polymeric network (IPN), and semi-interpenetrating polymeric network (semi-IPN) hydrogels on the basis of the crosslinking mechanism (Ullah et al., 2015). In homo-polymer hydrogels, the crosslinking network is made by the polymerization of a single water-soluble monomer (Iizawa et al., 2007), whereas, in co-polymeric hydrogels, it is formed by two or more different monomer units, having at least one hydrophilic monomer unit (Lipatov, 2002). When one linear polymer penetrates another crosslinked network without any chemical bonds, the polymer system is termed semi-IPN (Zhang et al., 2009). It is mostly synthesized through the use of a polymerization initiator in a monomer solution to bind two polymers together and immersed in pre-polymerized hydrogels (Lipatov, 2002). Semi-IPN can efficiently show a dynamic response to temperature or pH due to its un-restricted elastic network and is considered promising for bone and tissue engineering. Inter-penetrating network hydrogels can generate dense hydrogel matrices with effective drug-loading, higher mechanical features, and show controlled physical characteristics (Maolin et al., 2000; Lipatov, 2002; Liou et al., 2010).

Certain hydrogels have the capability to respond to external stimuli and such hydrogels are termed stimuli-responsive hydrogels. The network structure, volume, mechanical properties, and other features of such hydrogels change when the stimulus is applied. These hydrogels can be physically responsive, chemical responsive, and biochemical responsive hydrogels based on their response to the type of external stimulus. Temperature, light, pressure, electric, and magnetic fields are examples of physical stimuli, while chemical agents, ionic strength, and pH constitute chemical stimuli. In addition, the hydrogels that respond to enzymes, ligands or antigens, and other biochemical drugs are termed biochemical stimuli-responsive (Ahmed, 2015). Thermo-responsive
hydrogels are usually liquid at \( \sim 25^\circ C \) temperature which is quickly gelled at physiological or specific local tissue temperature and are commonly used as injectable hydrogels for bone and tissue engineering (Nagahama et al., 2013; Sood et al., 2016). Such hydrogels have the ability to reach the defective bone site with the use of minimally invasive surgery, can be used for fixation of injured bone tissue, treating any shape of bone deformity, and might be utilized for delivery of drugs (Soundarya et al., 2018).

### 4.3. Synthesis and preparation of hydrogels

Hydrogel networks are primarily formed by two types of crosslinking: chemical and physical. Ionic, electrostatic, and hydrophobic interactions crystallization and hydrogen bonding all contribute to the connectivity of physical hydrogels (Akhtar et al., 2016). Chemically crosslinked hydrogels can be synthesized using a variety of processes, including Michael addition, Schiff base reactions, free radical polymerization, Diels-Alder cycloadditions, and other click chemistry reactions (Huang et al., 2017). Macromolecules fold into scaffolds with well-defined structures and functions owing to physical non-covalent bonding mechanisms (Zhang & Khademhosseini, 2017). Due to its ability to self-assemble under particular conditions and lack of dependency on crosslinkers, physical hydrogels are becoming increasingly popular among researchers. Recent reports revealed that a wide range of physical injectable hydrogels, such as stress-sensitive or ion-sensitive hydrogels, can now be made without any chemical discomfort (Ren et al., 2015). Ionic interactions are frequently physical injectable hydrogels, such as stress-sensitive or ion-sensitive hydrogels, which quickly gelled at physiological or specific local tissue temperature which is elevated temperatures generated through functional scaffolds can be controlled to efficiently ablate tumor cells caused through surgery while also removing any remaining tumor cells, achieving the goal of bone tumor therapy.

In comparison to radio/chemotherapy, magneto/photothermal therapy has significantly lesser or minimum adverts effects and can successfully destroy tumor cells without causing damage to adjacent healthy tissue as cancerous cells have higher sensitivity to heat relative to healthy cells due to the differential expression of heat shock proteins (HSPs) involved in the cellular defense system against various stressors including heat (Di Mauro et al., 2018). Hence, the temperature elevation generated through functional scaffolds results in late progressive apoptosis, irreversible protein denaturation, and cell membrane damage. Thus, functional scaffolds with outstanding magneto/photothermal properties can be used locally as magneto/photothermal agents. Additionally, these functional hydrogel scaffolds are biocompatible, increase bone mesenchymal stem cell (MSC) migration, adhesion, differentiation, proliferation, and enhance new bone formation in vivo (Przekora, 2019). Ma et al. developed a biomaterial scaffold modified with graphene oxide (GO) that has improved photothermal characteristics (Ma et al., 2016). The unique photothermal impact of functional scaffolds can be controlled to efficiently ablate tumor cells and prevent tumor growth in mice. Elevated temperatures caused through functional scaffolds have been shown to greatly decrease tumor cell proliferation and significantly
Injectable biomaterials enable minimally invasive procedures and offer a wide range of uses in bone regeneration. In comparison to conventionally examined scaffolds, injectable hydrogels have several advantages, such as being unique and irreplaceable for filling irregular defects, improving patient compliance with bone injury, and allowing tissue regrowth and regeneration in situ (Hou et al., 2004). Ma, H., et al. synthesized the injectable hydrogels for the synergistic delivery of doxorubicin, cisplatin and methotrexate for osteocarcinoma treatment. Schematic for their preparation are provided in Figure 6. Several biomaterials, such as HA, chondroitin sulfate, chitosan, collagen, and polypeptide, can be used as appropriate substances for the production of injectable hydrogels. According to the results of biological evaluations in vivo, they all possess excellent biocompatibility and biodegradability.

4.6. Collagen-based hydrogels

Collagen is a fibrous protein with unique physicochemical and structural properties that have been widely used in biological applications. Collagen-containing cells can move directly into hydrogel scaffolds through integrin, suggesting that collagen may be crucial for osteoconduction. Collagen, as a part of cartilage, is an excellent substance for regenerating bone tissue, particularly cartilage tissue, due to its ability to promote cell differentiation and intrinsic biocompatibility. Collagen’s key disadvantages are its weak mechanical characteristics and rapid disintegration rate, which inhibit MSC differentiation and proliferation, resulting in an insufficient effect of bone repair (Huang et al., 2017). To address the aforementioned concerns, great effort has been made to improve the performance of injectable hydrogels based on collagen in recent research, which has demonstrated a favorable therapeutic impact in a bone deficiency model. Hydrogels made with a PEG-PCL-PEG copolymer (PECE), collagen, and n-HA, collagen-based composite hydrogel, were successfully developed by Fu et al. Because the pure collagen hydrogel group lacks thermal sensitivities, the researchers covalently crosslinked the PECE into the collagen chain, so introducing heat sensitivities to the composite hydrogel (Fu et al., 2012). To investigate the temperature-sensitive property of composite hydrogel, a test tube inversion approach and rheological analysis were used. The composite hydrogel exhibited freedom flow characteristics at room temperature but began gelating around 37°C. Additionally, the ability of the composite hydrogel scaffolds to regenerate bone was assessed by injecting them into cranial lesions in New Zealand White rabbit models for 20 weeks. In comparison to the control group, the group injecting the hydrogel scaffolds revealed a greater capacity for bone repair, as determined by histological sections and micro-computed tomography images which are provided in Figure 7. Figure 7(A–C) depicts the variations in the left blank control, whereas Figure 7(D–F) depicts the formation of new bone in the right defects exposed to the PECE/Collagen/n-HA hydrogel composite for the same period as the left. There is a thin layer of new osteoid on the defect edges and the remaining bottom bone surface in both groups at 4 weeks. A high number of osteoblasts formed in the middle location of the
defects (Figure 7(D)), where some osteoid and a lot of blood vessel tissue had formed on the new bone matrix. However, in the blank defect, just a few new osteoid tissues were found (Figure 7(A)). However, we observe some inflammatory cells in the center of the treated defect, indicating that a modest inflammatory response may have been induced by the implant’s degradation. By week 12, the newly generated osteoid had matured into the cortical bone and had fused with the surviving host bone. Nonetheless, as compared to the blank defect (Figure 7(B)), the treated defect’s cortical bone layer was thicker, and some bone marrow was visible at the outside edge of the freshly created bone. After 20 weeks of surgery, a noticeable variation between the two groups persisted ($p < .05$), the blank defect (Figure 7(C)) was partially filled with newly formed cortical bone, but the treated defect (Figure 7(F)) was entirely padded by newly formed cortical bone tissue under the same magnification.

As a consequence of the in vivo investigations, the PECE/Collagen/n-HA composite hydrogel was found to be more biocompatible and capable of bone regeneration than the control group.

Fitzgerald et al. used collagen-based scaffolds to design a cell culture model in a 3D arrangement for prostate cancer bone metastasis to classify the model and analyze its potential for testing the delivery of gene therapies targeted at bone metastases (Fitzgerald et al., 2015). PC3 and LNCaP cell lines from prostate cancer were grown in two-dimensional (2D) conventional culture and particularly in comparison to 3D cell growth on three scaffolds based on collagen, including collagen and collagen composites containing nano-hydroxyapatite or glycosaminoglycan. Matrix metalloproteinase (MMP), viability, prostate-specific antigen (PSA), and cell proliferation production were all determined in the 3D model. In comparison to 3D, chemosensitivity to docetaxel therapy was assessed in 2D. Nanoparticles (NPs) with siRNA made with a functionalized cyclodextrin were used to evaluate gene silencing. On the scaffolds, PC3 and LNCaP were both actively invaded and proliferated. In PC3 cells, 3D culture resulted in decreased MMP1 and MMP9 secretion. In comparison, LNCaP cells grown in 3D released increased amounts of PSA, notably on the collagen and glycosaminoglycan scaffold. Both 3D-grown cell lines exhibited greater resistance to docetaxel therapy. In the 3D model, the cyclodextrin siRNA NPs were taken up by the cells and knocked off the endogenous GAPDH gene. To conclude, the development of a unique cell culture model in a 3D arrangement for prostate cancer bone metastasis has started, resulting in the first effective delivery of gene treatments in a 3D in vitro model. Further development of this model will aid in elucidating the pathophysiology of prostate cancer as well as accelerating the development of effective treatments that can penetrate the bone microenvironment for prostate cancer therapy.

4.7. Hyaluronic acid-based hydrogels

HA, $\beta$-1,4-d-glucuronic acid-$\beta$-1,3-N-acetyl-d-glucosamine, is a significant GAGs found in bone tissue, particularly cartilage, and may be the primary component of synovial fluid. In comparison to collagen, HA comes from a broader range of sources and is less expensive. Additionally, HA, as an endogenous, has lower immunogenicity than collagen. Specifically, it has been demonstrated that HA has a role in anti-inflammatory effects, degradation, proteoglycan release inhibition, and prostaglandin production inhibition, and cellular signaling (Kim et al., 2011). Furthermore, HA is a macromolecule...
composed of linear polysaccharides with a molecular weight of 100–8000 kDa with a structural formula that contains free OH, N-acetyl, and COOH groups. All of these classes are primary targets for enhancing structural organization and physiochemical properties. Furthermore, HA can be destroyed in living organisms by free radicals, hyaluronidase, and enzyme. In short, adjustable reactive groups and HA have been extensively used in bone tissue engineering to cure cartilage defects, rheumatoid arthritis, and osteoarthritis, depending on their functionality (Jeznach et al., 2018). Gurski et al. established a 3D culture system that was biomimetic for weakly adherent bone metastatic prostate cancer cells (C4-2B) for screening of anticancer drugs in vitro (Gurski et al., 2009). To that purpose, complementary hydrazide (HAADH) and aldehyde (HAALD) derivatives of HA were produced and studied. C4-2B cells were encapsulated in situ by simply combining HAADH and HAALD in the presence of the cells. Unlike cells grown in 2D monolayer culture, which exhibit an unusual spread morphology, cells growing in the HA matrix developed discrete clustered structures that expanded and merged, mimicking the growth of real tumors. Anticancer drugs applied to the medium around the cell/gel composite diffused into the gel and killed the trapped cells. The HA hydrogel method was effectively utilized to investigate the efficacy of the anticancer drug such as docetaxel, camptothecin, and rapamycin, both in combination and alone, as well as specificity, dosage, and timely responses. The anti-neoplastic responses of cells in the 2D monolayer and 3D hydrogel-based HA systems were different. We suggest that results obtained from 3D HA systems are preferable to those obtained from traditional 2D monolayers because the 3D model more properly reflects the microenvironment of cancer cells’ bone metastatic.

Yu et al. developed a hydrogel with curcumin (Cur) loaded chitosan (CS) nanoparticles (CCNP) encapsulated silk fibroin (SF)/HA esterified by methacrylate (HAMA) (CCNPs-SF/HAMA) for osteosarcoma therapy and bone regeneration using photocuring and ethanol treatment (Yu et al., 2021). In the CCNPs-SF/HAMA hydrogel, micro or nanofiber networks were discovered. The FTIR data showed that the alcohol vapor treatment increased the SF β-sheets, which resulted in the CCNPs-SF/HAMA hydrogel’s high compressive stresses and Young’s modulus. According to the water uptake investigation, SF decreased the CCNPs-SF/HAMA hydrogel water uptake slightly, whereas CCNPs increased it. Both SF and CCNPs enhanced the CCNPs-SF/HAMA hydrogel swelling ratio, as measured by the swelling kinetics. The cumulative release profile of the CCNPs-SF/HAMA hydrogel revealed that the release of Cur from the hydrogel was accelerated as the pH was reduced from 7.4 to 5.5. Additionally, the CCNPs-SF/HAMA hydrogel, as compared to CCNPs, had a longer-lasting drug release, which was desirable for long-term osteosarcoma treatment. The results of in vitro assays suggested that CCNPs-SF/HAMA hydrogel containing an equal Cur (150 g/mL) was anticancer and promoted osteoblast proliferation. These findings show that a CCNPs-SF/HAMA hydrogel with exceptional physical qualities and the ability to perform dual functions of osteosarcoma therapy and bone repair may be an attractive choice for local cancer therapy and bone regeneration.

4.8. Chitosan-based hydrogels

Chitosan (CS) is also a type of glycosaminoglycans (GAGs) found in cartilage tissue that interacts with signal transduction, growth factors, and adhesion cells directly or indirectly.
In other words, CS is a biocompatible polymer that has been shown to aid bone regeneration (Soundarya et al., 2018). CS has the benefit of being easily changed by its glucosamine residues (e.g. carboxymethylation, acylation, and alkylation) to increase its physicochemical characteristics and biological activities. The porous nature of the scaffold facilitates cell migration and tissue regeneration, and CS’s ability to produce porous structures is another benefit. Numerous strategies have been used over the last decade to develop an injectable hydrogel capable of forming a strong scaffold in situ, including redox and photoinitiator-guided polymerization. One point worth noting is that extended exposure to initiators and irradiation will result in cytotoxicity (Fedorovich et al., 2009). As a result, it is critical to create a moderate environment for injectable hydrogel network crosslinking. Schiff’s base reaction is a moderate reaction that can result in the formation of imine bonds through amino and aldehyde groups (Balakrishnan et al., 2013). Based on Schiff’s reaction, CS can be chosen as an appropriate biomaterial to make an injectable hydrogel due to the abundance of amino groups in its structure. Schematic illustration of hydrogel-assisted bone regeneration is provided in Figure 8 (Bai et al., 2018).

Tao et al. developed a thermosensitive hydrogel derived from CS to produce a VCM-nanoparticle (NPs)/Gel local drug delivery system (Tao et al., 2020). VCM-NPs were synthesized using quaternary ammonium CS and carboxylated CS nanoparticles (VCM-NPs) to improve the encapsulation efficiency and drug loading of VCM, to prevent infection and heal fractured bones simultaneously. A rabbit osteomyelitis model was used to assess this hydrogel. The disclosed multifunctional hydrogel system for local administration demonstrated bone regeneration promoting and anti-infection properties, indicating that it has substantial promise as a scaffold for

| Biomaterial | Mode of tumor treatment | Bone Regeneration | References |
|------------|-------------------------|-------------------|------------|
| Hydrogelated black TiO2 (H-TiO2) coating with biomimetic hierarchical micro/nanostuctures deposited on a titanium implant | In-vitro and in-vivo, the photothermal treatment caused S-2 bone tumor cells necrosis. | In-vitro, BMSC adhesion, proliferation, and osteogenic differentiation were enhanced by hierarchical micro/nanotopography on an implant. | (Zhang et al., 2019) |
| Polydopamine and cisplatin decorating an n-HA surface loaded in chitosan/alginate hydrogels | Photothermal therapy and chemotherapy for 4T1 breast tumor-bearing mice | The bifunctional hydrogel induced bone repair in the joint bones of rabbits. | (Luo et al., 2019) |
| Nanohydroxyapatite hybrid reduced graphene oxide (n-HA-RGO) hydrogel | The n-HA-RGO hydrogel induced photothermal therapy and killed almost all MG-63 osteosarcoma cells in vitro and in vivo. | The n-HA-rGO hydrogel promoted bone regeneration with the stimulation of osteoblast mineralization and collagen deposition in a rat cranial defect model. | (Saber-Samandari et al., 2019) |
| PECE/Collagen/n-HA hydrogel | The temperature-sensitive hydrogel significantly induced the bone regeneration in rabbits. | The PECE/Collagen/n-HA hydrogel composite showed significant therapeutic efficacy and directed bone regeneration performance compared to the self-healing process. | (Fu et al., 2012) |
| CCNPs-SF/HAMA hydrogel | The hydrogel provided the pH triggered release and effectively killed the MG-63 cells. | CCNPs-SF/HAMA hydrogel promoted the osteoblast proliferation. | (Yu et al., 2021) |
| Methacrylated gelatin/methacrylated chondroitin sulfate hydrogel hybrid gold nanorods (GNRs) and alginate | The hydrogel induced photothermal therapy and caused apoptosis of K7M2wt cells. | The hydrogel mimics the ECM, promoting mesenchymal stem cell proliferation and osteogenic differentiation. | (Liao et al., 2021) |
| hybrid hydrogel (UCNP-Au-Alg) via the complexation of up-conversion lanthanide-Au hybrid nanoparticles (NPs) and alginate | Photothermal induced the apoptosis of T24 cells and significantly reduced the tumor growth in mice. | The elastic hybrid hydrogel facilitated the repair of the bone structure due to its supportive function. | (Liu et al., 2021) |
| Bifunctional UV and Sr2+ double-crosslinked alginate (ALG)/alkylated gelatin (GelAGE) hydrogels incorporated with polydopamine (PDA) particles | Hydrogels effectively killed the MG63 osteosarcoma cells through the synergy of controlled DOX release and hyperthermia ablation. | Enhance the proliferative potential of rat bone mesenchymal stem cells (rBMSCs) and also the alkaline phosphatase (ALP) activity of cells, suggesting their osteogenic promotion ability. | (Chen et al., 2022) |
| hydrogels based on Furan-Sodium Alginite/bis-maleimide- Polyethylene Glycol/Copper doped Bioactive Glass-ceramic Microspheres (SA/PEG-CuBGM) | The hydrogel induced the photothermal therapy and effectively killed the K7M2-WT cancer cells. | The SA/PEG-CuBGM composite hydrogel group showed significantly accelerated proliferation of mBMSCs and induced the most efficient bone formation. | (Yang et al., 2021) |
| Curcumin-microsphere/IR820 coloaded hybrid methylcellulose hydrogel (Cur-MP/IR820 gel) | The Hydrogel induced hyperthermia mediated curcumin release and showed the K7M2wt osteosarcoma cells. | The hydrogel induced the bone regeneration via promoting the alkaline phosphatase expression and calcium deposition of bone mesenchymal stem cells. | (Tan et al., 2021) |
effective osteomyelitis treatment. Min et al. described the synthesis of CS-poly(dioxanone) copolymers with different amounts of poly(dioxanone) and free amino groups on the CS backbone (Min et al., 2019). The selected CS-poly(dioxanone) was combined with HA to form HA/CS-poly(dioxanone) polyelectrolyte complex NPs by an ionotropic gelation process, and this type of HA/CS-poly(dioxanone) polyelectrolyte complex NPs was used as a carrier for bone morphogenetic protein-2 (BMP-2) delivery. To achieve long-term BMP-2 release, the optimum BMP-2-encapsulated HA/CS-poly(dioxanone) NPs were embedded in CSglycerophosphate composite solutions to form various hydrogels. The gels were determined to be injectable at room temperature and to have a thermosensitive phase transition around physiological temperatures and pH values. Additionally, they demonstrated the ability to release BMP-2 in a nearly linear manner for several weeks while effectively retaining the encapsulated BMP-2’s bioactivity. Because the currently developed gel systems are completely biocompatible and biodegradable, they have a high potential for translation to the clinic to be used in bone repair and regeneration, where persistent and controlled stimulation from active signaling molecules and stable biomechanical scaffolds for housing recruited cells are frequently required simultaneously.

4.9. Micro/nanogels as functional drug delivery vehicles

Because of the rapid advancement of nanotechnology in recent decades, a wide range of nanomaterials, such as liposomes, nano micelles, nanoparticles, and nano/microgels, have been used in various fields (Wu et al., 2011; Chen et al., 2016; Zhang et al., 2017, 2018). These small molecules can easily pass vessels and localize to certain tissues, and they can also be functionalized with specific molecules to enable active targeting. As a result, this system will serve as an attractive platform for biomedical applications such as bone regeneration, cartilage repair, tumor therapy, and wound healing (Ding et al., 2013; Agrawal & Agrawal, 2018; Zhu et al., 2018). Nano/microgels, in comparison to other small substances, have a controllable nanoparticle size, a cell-adhesive porous structure, good biocompatibility, and a large surface area. Additionally, their stimuli-sensitivity, adaptable functional groups, and high water content make them an excellent biomaterial for life science applications. With an increasing appreciation and application of the material’s advanced and biocompatible properties, many biomaterials employed in micro/nanogels have received considerable interest due to their distinct advantages in terms of biological activity and polymer chain modification.

Microgels have attracted substantial attention in the field of tissue engineering in recent years due to their excellent biocompatibility, cost-effectiveness, and functional diversity (Heris et al., 2016). Additionally, the ability to enwrap macromolecule proteins, polypeptides, metal/nonmetal ions, or small molecule medicines contributes to tissue regeneration. Thus, various micro-based scaffolds were utilized to facilitate cellular migration and differentiation by acting as a favorable microenvironment. Wu et al. prepared a PNIPAM-based microgel system modified by PEG and galactose ligands. Additionally, PEG was used to minimize the gel system’s shrinking, and galactose ligands were combined with PNIPAM to boost the hydrogel’s cell viability (Wu et al., 2014). Moreover, a human hepatocarcinoma cell line (HepG2 cells), was enwrapped in this gel scaffold, and the experimental data demonstrated the expected phenomena of increased cell viability with increasing galactose ligand content. Li et al. developed a functional gelatin-based assembly injectable microgel containing stem cells (Li et al., 2018). The crosslinker used in this system was NH-PEG, which resulted in covalent bonding between the microgel building blocks. The hBMSCs were then encapsulated in a network based on NHS-treated assembled (NHSA) microgels, which allowed them to maintain excellent cell viability while also increasing cell migration. NHSA-microgels also demonstrated a higher level of chondrogenic gene expression, suggesting that this biocompatible microgel could be used in bone regenerative therapy.

Nanogels are spherical hydrogels with a nanoscale diameter that are formed by physically or chemically interconnecting aqueous architectures. Nanogels share some characteristics with hydrogels, including excellent biodegradability and controlled mechanical properties (Elkhoury et al., 2019). Nanogels can be utilized to encapsulate bioactive substances including miRNA or protein therapeutics, preserving biological activity in vitro and resulting in a more effective therapy effect in vivo than in situ injectable hydrogels and hydrogel scaffolds (Sasaki & Akiyoshi, 2010). Nanogels, due to their nanoscale and surface area, have a higher potential in drug delivery systems than microgels. For instance, drug-loaded nanogels can be activated with targetable compounds such as folinic acid, a targeted peptide, or an antibody, and then administered intravenously to tumors or osteoarthritis (Culver et al., 2016). In recent decades, stimuli-responsive nanogels, which varied their shape or other features in response to external conditions including temperature, pH, and physiochemical environment, have gained remarkable consideration in the field of bone tissue engineering, such as OA, RA, and bone defects, as well as fracture. Temperature changes can affect the internal network of the nanogel, as well as its size and interactions with foreign particles, resulting in the controlled release of loaded biomolecules (Qureshi & Khatoon, 2019). The thermosensitive derivative N-isopropylacrylamide (NIPAm) has been extensively utilized in biomedicine (Qian & Wu, 2013). NIPAm is hydrophilic below 32 °C (its lower critical solution temperature (LCST)). When the temperature surpasses the LCST, it becomes hydrophobic due to the aggregation of NIPAm units, causing the system to shrink. Furthermore, chain changes can control the LCST of pNIPAm (Chen et al., 2013). Off-targeted, unstable, or insoluble, bioactive compounds could be encapsulated in nanogels and deposited in inflammatory regions via target recognition or an enhanced permeability and retention (EPR) effect (Wang et al., 2018).

Table 1 illustrates the various types of hydrogel used for the treatment of bone tumor as well as bone regeneration.
We'll go through some of the most promising alternative hydrogel matrices that have shown great bone formation along with bone tumor therapy in several animal defect models.

5. Conclusion and perspective

The current review explores the recent advancements in the development of functionalized hydrogels for the treatment of bone tumors. A novel technique based on functionalized hydrogels has the potential to suppress tumor growth during the initial stages of treatment and boost bone repair during the late stages of treatment. The benefits of locally and systematically administered functionalized hydrogels have the potential to significantly enhance the survival rate of patients with bone tumors. The use of functionalized hydrogels in future clinical bone tumor treatments may offer new possibilities for increasing patient quality of life and decreasing mortality.

There are still numerous challenges that need to be resolved in actual applications in future studies. Although several investigations including in vitro or in vivo experimental studies have been undertaken to date, however, relatively few clinical trials have been conducted using a human model or human cells. To the best of our knowledge, the following are the specific reasons: (1) Hydrogels are often examined in subcutaneous models that do not accurately depict the complex microenvironment of bone diseases associated with fracture repair or major bone defect repair. (2) While the majority of the test animals are healthy young animals, the practical application of this bone tissue engineering approach is expected to occur in more mature individuals and the elderly, with certain complications. (3) In addition to model challenges, hydrogel storage is a difficult nut to crack, which adds to the complexity of using hydrogels in clinical applications. Hydrogels that swell during storage and transportation are more susceptible to disruption, which can result in medication leakage. To address this problem, dehydration following preparation is recommended; although, this method may alter the structure and properties of reswollen hydrogels. (4) Unlike natural bone tissue, most hydrogels are incapable of self-repair. This disadvantage will result in hydrogels being mechanically damaged during the implantation procedure or bone activity. (5) Numerous functional hydrogels with appropriate mechanical characteristics and high bioactivities have demonstrated beneficial therapeutic effects in vitro and in vivo. However, both the complex preparation techniques and the high cost of hydrogel scaffolds place significant constraints on their further development and use in clinical applications.

Based on the foregoing, numerous critical elements should be examined to further develop hydrogel application at the clinical stage. To begin, the rate at which hydrogels degrade should correspond to the rate at which bone defects regenerate. Second, a comprehensive and well-defined clinical criterion for tissue engineering should be developed; concurrently, quality control standards and safety evaluation for these hydrogels should be developed. Additionally, because patients’ needs vary, researchers should focus on precision medicine rather than the one-size-fits-all approaches that have gradually become the dominant path of biomaterial design in bone tumor therapy and tissue engineering. Meanwhile, because bone tumor therapy and tissue engineering are complex processes, and each biomaterial has distinct advantages, researchers must select appropriate biomaterials for use as bone repair scaffolds based on the application requirements. As a result, a low-cost, cell-free, and easy-to-manufacture hydrogel system must be designed as a platform for clinical trials, eventually benefiting humans.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Nature Science Foundation of Zhejiang Province (GF22H064147), Medical and Health Research Project of Zhejiang Province (2020KY995, 2022KY433), Science and Technology Project of Shaoxing (2018C30165, 2018C30149).

ORCID

Wenqing Liang http://orcid.org/0000-0001-9770-882X

References

Agrawal G, Agrawal R. (2018). Stimuli-responsive microgels and microgel-based systems: advances in the exploitation of microgel colloidal properties and their interfacial activity. Polymers 10:1631.
Ahmed EM. (2015). Hydrogel: preparation, characterization, and applications: a review. J Adv Res 6:105–21.
Akhtar MF, Hanif M, Ranjha NM. (2016). Methods of synthesis of hydrogels … a review. Saudi Pharm J 24:554–9.
Ali Gumustas S, Isyar M, Topuk S, et al. (2016). Systematic evaluation of drug-loaded hydrogels for application in osteosarcoma treatment. Curr Pharm Biotechnol 17:866–72.
Amini AA, Nair LS. (2012). Injectable hydrogels for bone and cartilage repair. Biomater 7:024105.
Bădălă AE, Radulescu DM, Niculescu A-G, et al. (2021). Recent advances in the treatment of bone metastases and primary bone tumors: an up-to-date review. Cancers 13:4229.
Bai X, Gao M, Syed S, et al. (2018). Bioactive hydrogels for bone regeneration. Bioact Mater 3:401–17.
Balakrishnan B, Joshi N, Banerjee R. (2013). Borate aided Schiff’s base formation yields in situ gelling hydrogels for cartilage regeneration. J Mater Chem B 1:5564–77.
Boehme K, Schleicher S, Traub F, et al. (2018). Chondrosarcoma: a rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration and therapeutic resistance. JMS 19:311.
Brown R, Links M. (1999). Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999:1–21.
Buwalda SJ, Boere KWM, Dijkstra PJ, et al. (2014). Hydrogels in a historical perspective: from simple networks to smart materials. J Control Release 190:254–73.
Buwalda SJ, Vermonden T, Hennink WE. (2017). Hydrogels for therapeutic delivery: current developments and future directions. Biomacromolecules 18:316–30.
Casanova MG, Maltinti S, Barbani N, et al. (1999). Effect of chitosan and dextran on the properties of poly (vinyl alcohol) hydrogels. J Mater Sci Mater Med 10:431–5.

Chen G, Roy I, Yang C, et al. (2016). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev 116: 2826–85.

Chen S, Wang Y, Zhang X, et al. (2022). Double-crosslinked bifunctional hydrogels with encapsulated anti-cancer drug for bone tumor cell ablation and bone tissue regeneration. Colloids Surf B Biointerfaces 213:112364.

Chen W-J, Jingushi S, Aoyama I, et al. (2004). Effects of FGF-2 on metastasizes of primary maxillary fracture repair in rabbit tibiae. J Bone Miner Metab 22:303–9.

Chen Y, Ballard N, Bon SA. (2013). Moldable high internal phase emulsion hydrogel objects from non-covalently crosslinked poly(N-isopropylacrylamide) nanogel dispersions. Chem Commun 49:1524–1526.

Chen Y, Hao Y, Huang Y, et al. (2019). An injectable, near-infrared light-responsive click cross-linked azobenzene hydrogel for breast cancer chemotherapy. J Biomed Nanotechnol 15:1923–36.

Chindamo G, Sapino S, Peira E, et al. (2020). Bone diseases: current approach and future perspectives in drug delivery systems for bone targeted therapeutics. Nanomaterials 10:875.

Chou AJ, Geller DS, Gorlick R. (2008). Therapy for osteosarcoma. Pediatr Drugs 10:315–27.

Cortini M, Baldini N, Avnet S. (2019). New advances in the study of bone remodeling and the role of osteoblasts in bone repair. J Bone Miner Metab 22:112364.

Culebras M, Barrett A, Pishnamazi M, et al. (2021). Wood-derived hydrogels with encapsulated anti-cancer drug for bone tumor cell ablation and bone tissue regeneration. Colloids Surf B Biointerfaces 213:112364.

Davis ME, Chen Z, Shin DM. (2010). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nanosci Technol Collect Rev Nature J 7:239–50.

Diehl KL, Kolesnichenko IV, Robotham SA, et al. (2016). Click and chemical functionalization hydrogel objects from non-covalently crosslinked poly(N-isopro-

Doebernitz D, Pinsky P. (2018). Injectable hydrogels for localized and sustained gene delivery. J Control Release 213:112364.

Elkhoury K, Russell CS, Sanchez-Gonzalez L, et al. (2019). Soft nanocarriers improve targeting and therapeutic efficacy in glioma. ACS Appl Mater Interfaces 11:1841–54.

Fu SZ, Ni PY, Wang BY, et al. (2012). Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. Biomaterials 33:4801–9.

Fujiwara T, Ozaki T. (2016). Overcoming therapeutic resistance of bone sarcomas: overview of the molecular mechanisms and therapeutic targets for bone sarcoma stem cells. Stem Cells Int 2016:2603092.

Gamberra S, Patino-Garcia A, Alfranca A, et al. (2021). RGB-marking to identify patterns of selection and neutral evolution in human osteosarcoma models. Cancers 13:203.

Gerski LA, Jha AK, Zhang C, et al. (2009). Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 30:6076–85.

Hakim DN, Pelly T, Kuldrenan M, et al. (2015). Benign tumors of the bone: a review. J Bone Oncol 4:37–41.

Han Y, Zeng Q, Li H, et al. (2013). The calcium silicate/alginite composite: preparation and evaluation of its behavior as bioactive injectable hydrogels. Acta Biomater 9:9107–17.

He Q, Huang Y, Wang S. (2018). Hofmeister effect-assisted one step fabrication of ductile and strong gelatin hydrogels. Adv Funct Mater 28: 1705069.

Hers HK, Daoud J, Sheibani S, et al. (2016). Vocal fold tissue regeneration: investigation of the viability, adhesion, and migration of human fibroblasts in a hyaluronic acid/gelatin microgel-reinforced composite hydrogel for vocal fold tissue regeneration. Adv Healthcare Mater 5:188.

Hodgson SM, McNelies SA, Abdullahu L, et al. (2017). Reproducible dendronized PEG hydrogels via SPAAC cross-linking. Biomacromolecules 18:4054–9.

Hosoya K, Poulson JM, Azuma C. (2008). Osteoradionecrosis and radiation induced bone tumors following orthovoltage radiation therapy in dogs. Vet Radiol Ultrasound 49:189–95.

Hou Q, Paul A, Shakesheff KM. (2004). Injectable scaffolds for tissue regeneration. J Mater Chem 14:1915–23.

Huang M-H, Yang M-C. (2008). Evaluation of glucan/polyvinyl alcohol blend wound dressing using rat models. Int J Pharm 346:38–46.

Huang Q, Zou Y, Arno MC, et al. (2017). Hydrogel scaffolds for differentiation of adipose-derived stem cells. Chem Soc Rev 46:6255–75.

Izawa T, Taketa H, Maruta M, et al. (2007). Synthesis of porous poly(N-isopropylacrylamide) gel beads by sedimentation polymerization and their morphology. J Appl Polym Sci 104:842–50.

Jaffe N. (2009). Osteosarcoma: review of the past, impact on the future. The American experience. Pediatr Adolesc Osteosarcoma 152:239–62.

Jemal A, Murray T, Ward E, et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55:10–30.

Jeznach O, Kolbuk D, Sajkiewicz P. (2018). Injectable hydrogels and nanocomposite hydrogels for cartilage regeneration. J Biomed Mater Res A 106:2762–76.

Kim IL, Mauck RL, Burdick JD. (2011). Hydrogel design for cartilage tissue engineering: a case study with hyaluronic acid. Biomaterials 32: 8771–82.

Kolambkar YM, Dupont KM, Boerckel JD, et al. (2011). An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 32:625–74.

Krishna R, Mayer LD. (2000). Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–83.

Li F, Truong VX, Fisch P, et al. (2018). Cartilage tissue formation through assembly of microgels containing mesenchymal stem cells. Acta Biomater 77:48–62.

Li X, Zou Q, Wei J, et al. (2021). The degradation regulation of 3D printed scaffolds for promotion of osteogenesis and in vivo tracking. Compos Part B Eng 222:109084.

Li Y, Tian H, Chen X. (2013). Hyaluronic acid based injectable hydrogels for localized and sustained gene delivery. J Control Release 213: e140–e141.

Fu S, Liang M, Wang Y, et al. (2019). Dual-modified novel biomimetic nanocarriers improve targeting and therapeutic efficacy in glioma. ACS Appl Mater Interfaces 11:1841–54.
Liao J, Han R, Wu Y, et al. (2021). Review of a new bone tumor therapy strategy based on bifunctional biomaterials. Bone Res 9:1–13.

Liao J, Jia Y, Wu Y, et al. (2020). Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy. Wiley Interdiscip Rev Nanobiotechnol 12:e1581.

Liao J, Shi K, Jia Y, et al. (2021). Gold nanorods and nanohydroxyapatite hybrid hydrogel for preventing bone tumor recurrence via postoperative photothermal therapy and bone regeneration promotion. Bioact Mater 6:2221–30.

Lindsey BA, Markel JE, Kleinerman ES. (2017). Osteosarcoma overview. Rheumatol Ther 4:25–43.

Liou G-S, Lin P-H, Yen H-J, et al. (2010). Highly flexible and optical transparent 6F-PI/TIO 2 optical hybrid films with tunable refractive index and excellent thermal stability. J Mater Chem 20:531–6.

Lipatov YS. (2002). Polymer blends and interpenetrating polymer networks at the interface with solids. Progr Polym Sci 27:1721–801.

Liu B, Gu X, Sun Q, et al. (2021). Injectable in situ induced robust hydrogel for photothermal therapy and bone fracture repair. Adv Funct Mater 31:2010779.

Liu C, Wang Z, Wei X, et al. (2021). 3D printed hydrogel/PCL core/shell fiber scaffolds with NIR-triggered drug release for cancer therapy and wound healing. Acta Biomater 131:314–25.

Liu H, Wang Y, Cui K, et al. (2019). Advances in hydrogels in organoids and organs-on-a-chip. Adv Mater 31:1902042.

Liu W, Sun J, Sun Y, et al. (2020). Multifunctional injectable protein-based hydrogel for bone regeneration. Chem Eng J 394:124875.

Liu Y, Yu Q, Chang J, et al. (2019). Nanobiomaterials from 0D to 3D for tumor therapy and tissue regeneration. Nanoscale 11:13678–708.

Lü S, Gao C, Xu X, et al. (2015). Injectable and self-healing carboxylate-based hydrogel for cell encapsulation. ACS Appl Mater Interfaces 7: 13029–37.

Luetteke A, Meyers PA, Lewis I, et al. (2014). Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40: 523–32.

Luo S, Wu J, Jia Z, et al. (2019). An injectable, bifunctional hydrogel with photothermal effects for tumor therapy and bone regeneration. Macromol Biosci 19:1900047.

Ma H, He C, Cheng Y, et al. (2015). Localized co-delivery of doxorubicin, cisplatin, and methotrexate by thermosensitive hydrogels for enhanced osteosarcoma treatment. ACS Appl Mater Interfaces 7: 27040–8.

Ma H, Jiang C, Zhai D, et al. (2016). A bifunctional biomaterial with photothermal effect for tumor therapy and bone regeneration. Adv Funct Mater 26:1197–208.

Ma P, Chen Y, Lai X, et al. (2021). The translational application of hydrogel for organoid technology: challenges and future perspectives. Macromol Biosci 21:2100191.

Macedo F, Ladeira K, Pinho F, et al. (2017). Bone metastases: an overview. Oncol Rev 11:321.

Maolin Z, Jun L, Min Y, et al. (2000). The swelling behavior of radiation prepared semi-interpenetrating polymer networks composed of polyNIPAAm and hydrophilic polymers. Radiat Phys Chem 58: 397–400.

Menéndez ST, Gallego B, Murillo D, et al. (2021). Cancer stem cells as a source of drug resistance in bone sarcomas. JCM 10:2621.

Meyers PA, Heller G, Healey J, et al. (1992). Chemotherapy for nonmetstatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:366–77.

Miller KD, Nogueira L, Mariotto AB, et al. (2019). Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin 69:363–85.

Min Q, Yu X, Liu J, et al. (2019). Chitosan-based hydrogels embedded with hyaluronic acid complex nanoparticles for controlled delivery of bone morphogenetic protein-2. Pharmaceuticals 11:214.

Misaghi A, Goldin A, Awad M, et al. (2018). Osteosarcoma: a comprehensive review. Sicot J 4:12.

Miwa S, Yamamoto N, Tsuchiya H. (2021). Bone and soft tissue tumors: new treatment approaches. Cancers 12:1832.

MM S. (2008). Biomaterials for bone materials tissue engineering. Mater Today 11:18–25.

Mousa SA, Bharral DJ. (2011). Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers 3:2888–903.

Murphy SV, Atala A. (2014). 3D bioprinting of tissues and organs. Nat Biotechnol 32:773–85.

Nagahama K, Takahashi A, Ohyia Y. (2013). Biodegradable polymers exhibiting temperature-responsive sol–gel transition as injectable biomedical materials. React Funct Polym 73:979–85.

Nair DP, Podgórski M, Chattani S, et al. (2014). The thiol-Michael addition click reaction: a powerful and widely used tool in materials chemistry. Chem Mater 26:724–44.

Nalbandian RM, Henry RL, Wilks HS. (1972). Artificial skin. II. Pluronic F-127 silver nitrate or silver lactate gel in the treatment of thermal burns. Journal of Biomedical Materials Research 6:583–90.

Park K. (2007). Nanotechnology: what it can do for drug delivery. J Control Release 120:1–3.

Prataetorius NP, Mandal TK. (2007). Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 1:37–51.

Przekora A. (2019). The summary of the most important cell-biomaterial interactions that need to be considered during in vitro biocompatibility testing of bone scaffolds for tissue engineering applications. Mater Sci Eng C Mater Biol Appl 97:1036–51.

Qian J, Wu F. (2013). Thermosensitive PNIPAM semi-hollow spheres for controlled drug release. J Mater Chem B 1:3464–3469.

Qing G, Li M, Deng L, et al. (2013). Smart drug release systems based on stimuli-responsive polymers. Mini Rev Med Chem 13:1369–80.

Qureshi MA, Khatoon F. (2019). Different types of smart nanogel for targeted delivery. J Sci Adv Mater Devices 4:201–212.

Rajani R, Gibbs CP. (2012). Treatment of bone tumors. Surg Pathol Clin 5: 301–18.

Ren K, He C, Xiao C, et al. (2015). Injectable glycopolypeptide hydrogels as biomimetic scaffolds for cartilage tissue engineering. Biomaterials 51:238–49.

Saber-Samandari S, Mohammad-Aghdam M, Saber-Samandari S. (2019). A novel magnetic bifunctional nanocomposite scaffold for photothermal therapy and tissue engineering. Int J Biol Macromol 138:810–818.

Sasaki N, Nishii S, Yamada K, et al. (2013). Effect of gelatin hydrogel sheet containing basic fibroblast growth factor on proximal sesamoid bone transverse fracture healing in the horse. J Equine Vet Sci 33: 210–4.

Sasaki Y, Akiyoshi K. (2010). Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 10:366–376.

Siegel RL, Miller KD, Fuchs HE, et al. (2021). Cancer statistics, 2021. CA A Cancer J Clin 71:7–33.

Sisú AM, Stana LG, Petrescu CI, et al. (2012). On the bone tumours: overview, classification, incidence, histopathological issues, behavior and review using literature data. Histopathol Rev Recent Adv 65–80.

Sood N, Bhardwaj A, Mehta S, et al. (2016). Stimuli-responsive hydrogels in drug delivery and tissue engineering. Drug Delivery 23:748–70.

Soundarya SP, Menon AH, Chandran SV, Selvamurugan N. (2018). Bone tissue engineering: scaffold preparation using chitosan and other biomaterials with different design and fabrication techniques. Int J Biol Macromol 119:1228–39.

Steinbichler TB, Dudás J, Skvortsov S, et al. (2018). Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology 53:156–67.

Svensson E, Christiansen CF, Ulrichsen SP, et al. (2017). Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open 7:e016022.

Tan B, Tang Q, Zhong Y, et al. (2021). Biomaterial-based strategies for maxillofacial tumor therapy and bone defect regeneration. Int J Oral Sci 13:9–16.

Tan B, Wu Y, Wu Y, et al. (2021). Curcumin-microsphere/lR820 hybrid bifunctional hydrogels for in situ osteosarcoma chemothermal therapy and bone reconstruction. ACS Appl Mater Interfaces 13: 31542–31553.

Tao J, Zhang Y, Shen A, et al. (2020). Injectable chitosan-based thermosensitive hydrogel/nanoparticle-loaded system for local delivery of vancomycin in the treatment of osteomyelitis. Int J Nanomed 15: 5855–71.
